February 1, 2000Annual Review of Medicine
Management of Patients with Hereditary Hypercoagulable Disorders
Population
Patients with hereditary hypercoagulable disorders, including common mutations and uncommon deficiencies
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports defect-specific anticoagulation decisions in hereditary thrombophilia; leaves open need for prospective validation.
Structured PICO
P
Population
Patients with hereditary hypercoagulable disorders, including common mutations (factor V Leiden, G20210A prothrombin gene) and uncommon deficiencies (antithrombin, protein C, or protein S deficiency)
I
Intervention
Primary prophylaxis and anticoagulant therapy
O
Outcome
Risk of thrombosis and recurrent venous thromboembolismhard clinical
Management of hereditary hypercoagulable states should be tailored to the specific defect, with high-risk deficiencies warranting more aggressive prophylaxis and prolonged anticoagulation compared to common, lower-risk mutations.
Cite This Study
Kearon et al. (2000) studied this question.